-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fipaxalparant in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fipaxalparant in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Fipaxalparant in Idiopathic Pulmonary Fibrosis Drug Details: Fipaxalparant (HZN-825) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fipaxalparant in Systemic Sclerosis (Scleroderma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fipaxalparant in Systemic Sclerosis (Scleroderma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Fipaxalparant in Systemic Sclerosis (Scleroderma) Drug Details: Fipaxalparant (HZN-825) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – 2-CCPA in Osteoarthritis Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - 2-CCPA in Osteoarthritis Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.2-CCPA in Osteoarthritis PainDrug Details:2-CCPA is under development for osteoarthritis pain of knee. It...
-
Company Profile
NewLSL Property Services Plc – Company Profile
LSL Property Services Plc (LSL) is a provider of residential property services. The services offered by the company include financial services, residential sales, lettings, marketing, surveying, conveyancing and advice on mortgages and non-investment insurance products. It also offers services to mortgage lenders including valuations and panel management services, property management services, estate agency and other related services. The company markets its business under various brands such as Your Move and Reeds Rains, Linear Financial Solutions, Homefast, The Mortgage Alliance, Templeton...
Add to Basket -
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – RPI-002
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry RPI-002 Drug Details RPI-002 is under development for the treatment of chemotherapy induced neuropathic...
-
Product Insights
Net Present Value Model: HZN-825
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model HZN-825 Drug Details HZN-825 is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – 2-CCPA
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry 2-CCPA Drug Details 2-CCPA is under development for the treatment of atherosclerosis, osteoarthritis pain...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – HZN-825
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry HZN-825 Drug Details HZN-825 is under development for the treatment of skin manifestation of...
-
Product Insights
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
According to the recently published report 'Lysophosphatidic Acid Receptor 1 – Drugs In Development, 2022'; Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) pipeline Target constitutes close to 10 molecules. Out of which approximately 10 molecules are developed by Companies. Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) – Lysophosphatidic acid receptor 1 is a G protein-coupled receptor that binds the lipid signaling molecule lysophosphatidic acid (LPA). Lysophosphatidic acid (LPA) receptor belongs to a...
-
Product Insights
Apolipoprotein A (APOA or LPA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players
Apolipoprotein A (APOA or LPA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Apolipoprotein A (APOA or LPA) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and...